Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404660 · ClinicalTrials.gov registry record · Phase 1
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
A Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, sponsored by Autolus Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT04404660 is a Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by Autolus Limited. The registered enrollment target is 153 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT04404660, a Phase 1 study of Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Autolus Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
Conditions Studied
Interventions
- BIOLOGICAL AUTO1
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California San Diego Health (UCSD) - La Jolla
- University of California Davis (UC Davis) - Sacramento
- University of California San Francisco (UCSF) - San Francisco
Florida
- University of Miami - Miami
- H Lee Moffitt Cancer Center - Tampa
New York
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester - Rochester
Colorado
- Colorado Blood Cancer Institute (CBCI) - Denver
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Kansas
- University of Kansas - Kansas City
Maryland
- University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04404660
The ClinicalTrials.gov registry entry for NCT04404660 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Autolus Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which AUTO1 is the first listed.
NCT04404660 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04404660 about?
NCT04404660 is a clinical study titled "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)". This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
What is the current status of trial NCT04404660?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2020-06-03. Estimated completion is 2029-06-30.
What conditions does trial NCT04404660 study?
This clinical trial studies the following conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT04404660?
The interventions under investigation include: AUTO1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04404660?
This trial is sponsored by Autolus Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04404660 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
RECRUITING · Phase 1
-
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.